Acrux strengthens leadership with Chief Medical Officer appointment ahead of Phase III
Acrux Limited (ASX:ACR) has appointed Dr Jolanta Airey MD as its Chief Medical Officer, adding a senior physician-executive to the team charged with advancing its Female Testosterone treatment.
Dr Airey will be a key member of the leadership team tasked with steering the treatment through its pending Phase III FDA trials and its subsequent penetration of addressable markets across the US, Europe, Australia and other target regions.
For investors tracking the specialty pharma company’s lead asset, the appointment brings experienced clinical leadership to a pathway that management describes as offering a first mover advantage.
When big ASX news breaks, our subscribers know first
A leader with direct experience in Acrux’s testosterone platform
Dr Airey’s strongest credential is her direct familiarity with Acrux’s own formulation. She served as a Medical Monitor for the trials that led to the successful launch of Acrux’s male testosterone product, Axiron®. This kind of specific, hands-on experience with a company’s exact formulation is rare in a new senior hire.
She is a physician by training and a biopharmaceutical executive with more than 20 years of international experience. That experience spans the full clinical development lifecycle, from early-phase trials through to global product approvals, across therapeutic areas including immunology, acute neurology, rheumatology, respiratory disease, dermatology, haematological malignancies and infectious diseases.
Her recent and senior roles include:
-
Chief Medical Officer, Cynata Therapeutics Ltd (2021–2026), guiding the clinical and medical strategy of a cell-based therapy pipeline involving extensive Phase III registrational studies
-
Director, Translational Development at CSL Limited
-
Senior roles with Biota Pharmaceuticals, Inc and Kendle International/INC Research
-
Chair and member of multiple Data Safety Monitoring Committees and Safety Review Committees since 2014
Dr Airey holds a medical degree from Vilnius University in Lithuania and is registered with the UK’s General Medical Council (GMC) and the Lithuanian Ministry of Health.
CEO Commentary
“I want to personally welcome Dr Airey to Acrux’s leadership team. She will be a valuable resource as the Company sets about delivering all the critical milestones in Female Testosterone’s development strategy. She will help us progress the work required to get The Phase III FDA clinical trial for Female Testosterone underway. Dr Airey will also be an important member of the Acrux team holding discussions with potential co-development partnerships for this treatment, tie ups that will de-risk Female Testosterone’s clinical trial process and expedite its launch into target markets. I look forward to working with Dr Airey to realise the value inherent in both Female Testosterone and other IP created by Acrux, including its proven MDTS Technology.” said John Warmbrunn, CEO and Managing Director.
Understanding Female Testosterone and the first mover opportunity
Acrux’s Female Testosterone treatment targets Hypoactive Sexual Desire Disorder (HSDD) in women.
The HSDD market opportunity Acrux is targeting has been sized at US$6.6 billion annually across the total US addressable population, with no currently FDA-approved competitor product and a regulatory pathway the FDA clarified in January 2026.
An experienced Chief Medical Officer with direct testosterone-formulation and Phase III experience improves the prospects of a well-designed and efficiently executed trial. Management has referenced a first mover advantage for the treatment, supported by Acrux’s proven MDTS Technology and its 25-year track record as a specialty pharma company.
Why this appointment matters for the investment case
The appointment connects to potential value creation for the company across three areas:
-
De-risking the clinical pathway through experienced leadership over Phase III design and execution.
-
Partnership potential, with the Chief Medical Officer supporting discussions with potential co-development partnerships intended to de-risk the trial process and expedite launch.
-
Broader IP leverage, as her role extends to advancing other parts of Acrux’s IP portfolio, including MDTS Technology.
Acrux’s MDTS platform has already generated milestone income through its Lenzetto licensing deal with Gedeon Richter Plc, a structure worth up to AUD $5.4 million across three tranches that demonstrates the commercial model the company intends to replicate for Female Testosterone.
| Focus Area | What Dr Airey Brings | Why It Matters to Investors |
|---|---|---|
| Phase III FDA trial | Direct testosterone-formulation and Phase III experience | Supports a better-designed pivotal study |
| Co-development | Track record leading international teams | Supports de-risking and a faster potential launch |
| Broader IP | Full lifecycle experience to global approvals | Potential value across the MDTS portfolio |
Next steps: progressing toward Phase III
The disclosed forward path centres on getting the Phase III FDA clinical trial for Female Testosterone underway and pursuing discussions with potential co-development partnerships.
Incoming CMO Commentary
“I am excited to be joining the Acrux leadership team as the Company advances the development strategy for its Female Testosterone treatment, which offers real hope for women suffering from Hypoactive Sexual Desire Disorder. It will be great to be part of the team bringing to market such a unique treatment that comes with a clear-cut first mover advantage. And I also look forward to playing a role in advancing the development and market acceptance of other parts of Acrux’s IP portfolio,” said Dr Jolanta Airey, incoming Chief Medical Officer.
The appointment aligns with the company’s stated ambition to realise the value inherent in both Female Testosterone and the wider IP portfolio created by Acrux.
Don’t Miss the Next ASX Healthcare Breakout
Get FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis already done for you. Over 20,000 subscribers rely on Big News Blast to stay ahead of market-moving announcements the moment they drop. Click the “Free Alerts” button to start receiving real-time alerts today.